Should I buy or sell Denali Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks .

What is Denali Therapeutics' stock price target for 2024?

10 analysts have issued 1 year price targets for Denali Therapeutics' shares. Their DNLI share price targets range from $28.00 to $105.00. On average, they predict the company's share price to reach $50.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts .

How have DNLI shares performed in 2023?

Denali Therapeutics' stock was trading at $27.81 on January 1st, 2023. Since then, DNLI shares have decreased by 33.9% and is now trading at $18.37. View the best growth stocks for 2023 here .

Are investors shorting Denali Therapeutics?

Denali Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 9,560,000 shares, a decrease of 10.9% from the October 31st total of 10,730,000 shares. Based on an average daily trading volume, of 854,200 shares, the days-to-cover ratio is currently 11.2 days. Approximately 8.4% of the company's shares are short sold. View Denali Therapeutics' Short Interest .

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our DNLI earnings forecast .

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.09. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $11.16 million. Denali Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 11.54%. The firm's revenue for the quarter was down 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.84) earnings per share.

What ETFs hold Denali Therapeutics' stock?

ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , BNY Mellon Innovators ETF (BKIV) , Principal Healthcare Innovators ETF (BTEC) , Harbor Corporate Culture Small Cap ETF (HAPS) and Invesco Nasdaq Biotechnology ETF (IBBQ) . ProShares Ultra Nasdaq Biotechnology (BIB) .

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com . Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX) , Editas Medicine (EDIT) , Intellia Therapeutics (NTLA) , Sangamo Therapeutics (SGMO) , Kratos Defense & Security Solutions (KTOS) , CRISPR Therapeutics (CRSP) , Anavex Life Sciences (AVXL) , NVIDIA (NVDA) , Invitae (NVTA) and Pretium Resources (PVG) .

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.62%), Wellington Management Group LLP (5.27%), Bank of New York Mellon Corp (1.43%), Federated Hermes Inc. (0.98%), Northern Trust Corp (0.81%) and FMR LLC (0.77%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth , Carole Ho , David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne , Ryan J Watts, Ryan J Watts , Steve E Krognes, Steve E Krognes , Vicki L Sato and Vicki L Sato . View institutional ownership trends .

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

Denali Therapeutics Stock Price, News & Analysis (NASDAQ:DNLI)

$18.37

-0.37 (-1.97%)

(As of 12/8/2023 ET)

Compare

Today's Range: $18.01
▼
$18.72
50-Day Range: $16.20
▼
$21.83
52-Week Range: $15.45
▼
$33.31

Volume: 800,496 shs
Average Volume: 742,418 shs
Market Capitalization: $2.54 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.00

Denali Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 172.2% Upside
$50.00 Price Target
Short Interest: Bearish
8.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.84
Upright™ Environmental Score
News Sentiment: 0.37
Based on 5 Articles This Week
Insider Trading: Selling Shares
$105,641 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.01) to ($2.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

276th out of 954 stocks

Biological Products, Except Diagnostic Industry

32nd out of 129 stocks

3.5

Analyst's Opinion

Consensus Rating
Denali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.00, Denali Therapeutics has a forecasted upside of 172.2% from its current price of $18.37.
Amount of Analyst Coverage
Denali Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.41% of the float of Denali Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Denali Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Denali Therapeutics has recently decreased by 10.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Denali Therapeutics does not currently pay a dividend.
Dividend Growth
Denali Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Denali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Denali Therapeutics is -0.84.

3.0

News and Social Media Coverage

News Sentiment
Denali Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Denali Therapeutics this week, compared to 2 articles on an average week.
Search Interest
15 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
9 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,641.00 in company stock.
Percentage Held by Insiders
Only 7.90% of the stock of Denali Therapeutics is held by insiders.
Percentage Held by Institutions
78.04% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Denali Therapeutics are expected to decrease in the coming year, from ($1.01) to ($2.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Denali Therapeutics is -18.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Denali Therapeutics is -18.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Denali Therapeutics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Denali Therapeutics Stock (NASDAQ:DNLI)

Denali Therapeutics Inc., a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; and DNL343 eIF2B Activator program for amyotrophic lateral sclerosis. The company's other programs comprise SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DNLI Stock News Headlines

December 8, 2023 | americanbankingnews.com

Head-To-Head Review: Denali Therapeutics (NASDAQ:DNLI) and Innate Pharma (OTCMKTS:IPHYF)

December 7, 2023 | finance.yahoo.com

Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report?

December 8, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 7, 2023 | americanbankingnews.com

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Buy" by Analysts

December 5, 2023 | finance.yahoo.com

After losing 39% in the past year, Denali Therapeutics Inc. (NASDAQ:DNLI) institutional owners must be relieved by the recent gain

November 27, 2023 | finance.yahoo.com

Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High?

November 24, 2023 | benzinga.com

Denali Therapeutics Stock (NASDAQ:DNLI), Analyst Ratings, Price Targets, Predictions

November 24, 2023 | benzinga.com

Denali Therapeutics Stock (NASDAQ:DNLI) Dividends: History, Yield and Dates

December 8, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 19, 2023 | morningstar.com

Denali Therapeutics Inc DNLI

November 9, 2023 | markets.businessinsider.com

Promising Outlook for Denali Therapeutics: Leveraging the Superiority of TV Platform and OTV Approach

November 8, 2023 | finanznachrichten.de

Denali Therapeutics Inc.: Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

November 7, 2023 | tmcnet.com

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

November 7, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

November 6, 2023 | finance.yahoo.com

Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet

November 1, 2023 | markets.businessinsider.com

Optimistic Outlook for Denali Therapeutics: Emphasis on Promising Amyloid Clearance Kinetics and Potential Late-Stage Development

October 5, 2023 | finance.yahoo.com

Shareholders in Denali Therapeutics (NASDAQ:DNLI) are in the red if they invested three years ago

October 2, 2023 | msn.com

Denali's New Summit: Changing Hunter Syndrome Landscape

September 7, 2023 | finance.yahoo.com

Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?

September 6, 2023 | markets.businessinsider.com

Denali Therapeutics (DNLI) Receives a New Rating from B.Riley Financial

August 31, 2023 | markets.businessinsider.com

Jefferies Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)

August 30, 2023 | finance.yahoo.com

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

August 29, 2023 | finance.yahoo.com

Invaio achieves first registration for citrus greening solution featuring Trecise™ technology

August 11, 2023 | msn.com

Cantor Fitzgerald Reiterates Denali Therapeutics (DNLI) Overweight Recommendation

August 10, 2023 | finance.yahoo.com

Pinning Down Denali Therapeutics Inc.'s (NASDAQ:DNLI) P/S Is Difficult Right Now

August 9, 2023 | finanznachrichten.de

Denali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 9, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Denali Therapeutics (DNLI)

See More Headlines

Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DNLI
CUSIP: N/A
CIK: 1714899
Web: www.denalitherapeutics.com
Phone: (615) 866-8548
Fax: N/A
Employees: 447
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $50.00
High Stock Price Target: $105.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +172.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-325,990,000.00
Net Margins: -36.51%
Pretax Margin: -36.51%
Return on Equity: -11.54%
Return on Assets: -9.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.06
Quick Ratio: 16.06

Sales & Book Value

Annual Sales: $340.81 million
Price / Sales: 7.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.68 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 138,197,000
Free Float: 127,279,000
Market Cap: $2.54 billion
Optionable: Optionable
Beta: 1.11

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Ryan J. Watts Ph.D. (Age 47)
Co-Founder, President, CEO & Director
Comp: $1.04M
Dr. Alexander O. Schuth M.D. (Age 50)
Co-Founder, CFO, COO & Secretary
Comp: $737.2k
Dr. Marc Tessier-Lavigne Ph.D. (Age 63)
Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Comp: $58.23k
Dr. Carole Ho M.D. (Age 50)
Chief Medical Officer & Head of Development
Comp: $737.2k
Mr. Tyler M. Nielsen (Age 45)
Senior Vice President of Corporate Finance
Dr. Dana Andersen
Chief Technical and Manufacturing Officer
Mr. Joe Lewcock Ph.D.
Chief Scientific Officer
Dr. Laura Hansen
Vice President of Investor Relations
Mr. Chris Walsh
General Counsel
Mr. Mark Rowen
Vice President of Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DNLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings or view top-rated stocks.
What is Denali Therapeutics' stock price target for 2024?: 10 analysts have issued 1 year price targets for Denali Therapeutics' shares. Their DNLI share price targets range from $28.00 to $105.00. On average, they predict the company's share price to reach $50.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price.
View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts.
How have DNLI shares performed in 2023?: Denali Therapeutics' stock was trading at $27.81 on January 1st, 2023. Since then, DNLI shares have decreased by 33.9% and is now trading at $18.37.
View the best growth stocks for 2023 here.
Are investors shorting Denali Therapeutics?: Denali Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 9,560,000 shares, a decrease of 10.9% from the October 31st total of 10,730,000 shares. Based on an average daily trading volume, of 854,200 shares, the days-to-cover ratio is currently 11.2 days. Approximately 8.4% of the company's shares are short sold.
View Denali Therapeutics' Short Interest.
When is Denali Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our DNLI earnings forecast.
How were Denali Therapeutics' earnings last quarter?: Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.09. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $11.16 million. Denali Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 11.54%. The firm's revenue for the quarter was down 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.84) earnings per share.

What ETFs hold Denali Therapeutics' stock?: ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), BNY Mellon Innovators ETF (BKIV), Principal Healthcare Innovators ETF (BTEC), Harbor Corporate Culture Small Cap ETF (HAPS) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB).
What is Ryan Watts' approval rating as Denali Therapeutics' CEO?: 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Denali Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).
When did Denali Therapeutics IPO?: (DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.
Who are Denali Therapeutics' major shareholders?: Denali Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.62%), Wellington Management Group LLP (5.27%), Bank of New York Mellon Corp (1.43%), Federated Hermes Inc. (0.98%), Northern Trust Corp (0.81%) and FMR LLC (0.77%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.
How do I buy shares of Denali Therapeutics?: Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DNLI) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial